KaloBios Pharmaceuticals, Inc. Initiates Phase 1/2 Trial of KB002 Engineered Monoclonal Antibody in Persistent Asthma
PALO ALTO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase 1/2 clinical study of KB002, the company’s anti-GM-CSF monoclonal antibody, as a potential treatment for persistent asthma.